The pharmaceutical industry is increasingly turning to artificial intelligence (AI) to enhance decision-making, improve efficiency, and reduce risk in drug development. This executive summary, sponsored by Intelligencia AI, shares various perspectives from a range of industry leaders – a professor, solution provider, consultancy, and pharma stakeholder – to discuss the role of AI in de-risking pharmaceutical portfolios on an exclusive webcast.
The experts featured on the webcast shared insights on AI’s current impact and the foundational steps required for successful implementation. The discussion highlighted the importance of clean, structured data and the need for companies to balance in-house data management with strategic partnerships.
An executive summary of the webcast from Intelligencia AI showcases AI’s ability to assess the probability of technical and regulatory success (PTRS) and provide data-driven insights that support more strategic decision-making.
By downloading the executive summary, business leaders can explore how AI can help drive growth in two key areas: